Clinical trials: Sunitinib, completed
Metastatic Renal Cell Carcinoma
CRLX101(NLG207) in Combination With Bevacizumab for Metastatic Renal Cell Carcinoma (mRCC) Versus Standard of Care (SOC)
This study to evaluate treatment in patients with metastatic renal cell carcinoma (RCC) which has progressed through 2 to 3 prior lines of therapy, with the investigational drug CRLX101 in combination with bevacizumab compared to…
- Trial name
- NCT02187302
- Testing
- CRLX101, Bevacizumab, Standard of Care (Investigator Choice)
- Where
- 43 sites in United States, South Korea
- Volunteers
- 115 people
- Sponsor
- NewLink Genetics Corporation
Renal Cell Carcinoma
VEGF Imaging in Renal Cell Carcinoma
The primary objective of the study is to evaluate the feasibility of 89Zr-bevacizumab PET imaging as a biomarker before and during treatment with sunitinib or bevacizumab plus interferon in patients with RCC.
- Trial name
- Renimage (NCT00831857)
- Testing
- 89Zr-Bevacizumab PET-scan
- Where
- Netherlands
- Volunteers
- 26 people
- Sponsor
- University Medical Center Groningen
Urothelial Cancer, Bladder Cancer
SU011248 for Platinum-Refractory Urothelial Cancer Evaluation Trial
The purpose of this study is to find out if SU011248 works and if it is safe in patients with advanced transitional cell carcinoma.
- Conditions
- Urothelial Cancer, Bladder Cancer, Adult
- Trial name
- SPRUCE (NCT00578526)
- Testing
- SU011248
- Where
- 5 sites in Canada
- Volunteers
- 64 people
- Sponsor
- AHS Cancer Control Alberta
Advanced Cancer
Bevacizumab in Multiple Phase I Combinations
The goal of this clinical research study is to find the highest tolerable dose of Avastin™ that can be given in combination with 4 other study drug/drug combinations.
- Trial name
- NCT00543504
- Testing
- Bevacizumab, Sorafenib, Erlotinib
- Where
- United States
- Volunteers
- 343 people
- Sponsor
- M.D. Anderson Cancer Center
Renal Cell Carcinoma
Community Oncology Setting Disease Outcomes of Sorafenib (Nexavar) Use in Advanced Renal Cell Carcinoma
A retrospective medical record abstraction study of at least 200 advanced renal cell carcinoma patients treated in the following settings: Patients with advanced renal cell carcinoma treated with Sorafenib (Nexavar) as…
- Trial name
- NCT00876382
- Where
- 8 sites in United States
- Volunteers
- 47 people
- Sponsor
- SCRI Development Innovations, LLC
Metastatic Breast Cancer
SU11248 as Consolidation After Response to Taxanes in Metastatic Breast Cancer
This study tests the hypothesis that SU11248 can delay tumor progression after tumor mass reduction by taxanes. This is a dual-arm open-label randomized multicenter phase II clinical trial with 2:1 randomization evaluating the…
- Trial name
- NCT00270413
- Testing
- SU11248
- Where
- 13 sites in Belgium
- Volunteers
- 19 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Cancer
A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer
This is an open label, multi-center, Phase 1/2 study of BBI503 administered in combination with selected anti-cancer therapeutics in adult patients with advanced cancer.
- Trial name
- NCT02483247
- Testing
- BBI503, Capecitabine, Doxorubicin
- Where
- 8 sites in United States, Canada
- Volunteers
- 165 people
- Sponsor
- Sumitomo Pharma America, Inc.
B-cell Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma
Sunitinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
This phase II trial is studying how well sunitinib works in treating patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.
- Conditions
- B-cell Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia
- Trial name
- NCT00398112
- Testing
- sunitinib malate, pharmacological study, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Renal Cell Cancer, GIST
Evaluation of Cognitive Function of Patients With Sunitinib or Sorafenib
Patients with advanced kidney cancer or GIST (Gastro Intestinal Stromal Tumor: this is a tumor of the intestines) may be eligible for treatment with one of the following drugs: sunitinib (Sutent ®) or sorafenib (Nexavar ®).
- Trial name
- NCT01246843
- Where
- Netherlands
- Volunteers
- 50 people
- Sponsor
- Radboud University Medical Center
Prostate Cancer
Study of SU11248 in Men With Advanced Prostate Cancer
There are nearly 30,000 deaths per year in the United States from prostate cancer, making this a large and important target patient population for new cancer treatments.
- Trial name
- NCT00299741
- Testing
- Sunitinib
- Where
- 3 sites in United States
- Volunteers
- 36 people
- Sponsor
- Massachusetts General Hospital
Urinary Tract Urothelial Carcinoma
Bacillus Calmette-Guerin Followed by Sunitinib for the Treatment of High Risk Non-muscle Invasive Lower Urinary Tract Urothelial Carcinoma
A majority of patients with bladder cancer have disease confined to the inner lining of the bladder. Patients with high risk features (high grade tumors, tumors invading into a deeper superficial layer) are routinely treated with…
- Trial name
- Sutent (NCT00794950)
- Testing
- Sunitinib
- Where
- 2 sites in United States
- Volunteers
- 43 people
- Sponsor
- University of Michigan
Breast Cancer
Exploratory Study of Sunitinib Malate as a Component of Neoadjuvant Therapy for Breast Cancer
The combination of paclitaxel, doxorubicin, and cyclophosphamide is a standard neoadjuvant (given before surgery) treatment for patients that have either inoperable or operable breast cancer.
- Trial name
- NCT00656669
- Testing
- sunitinib alone, sunitinib plus paclitaxel, doxorubicin and cyclophosphamide
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Indiana University
Carcinoma, Renal Cell
A Pivotal Study Of SU011248 In The Treatment Of Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma.
To assess the safety and efficacy of SU011248 in patients with metastatic, refractory renal cell carcinoma
- Trial name
- NCT00077974
- Testing
- SU011248
- Where
- 15 sites in United States
- Volunteers
- 106 people
- Sponsor
- Pfizer
Adult Malignant Fibrous Histiocytoma of Bone, Desmoid Tumor
Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas
RATIONALE: Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Conditions
- Adult Malignant Fibrous Histiocytoma of Bone, Desmoid Tumor, Endometrial Cancer, Ovarian Cancer
- Trial name
- NCT00474994
- Testing
- sunitinib malate
- Where
- 2 sites in United States
- Volunteers
- 53 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Metastatic Renal Cell Carcinoma
Epidemiological Study to Identify Prognosis and Predictive Biomarkers for Advanced or Metastatic Renal Cell Carcinoma
Multicentric and prospective epidemiological study (NON INTERVETIONAL) to identify prognosis and predictive biomarkers of response to sunitinib and pazopanib as first line therapy in metstatic renal cell carcinoma.
- Trial name
- SOGANG (NCT03519542)
- Testing
- Sunitinib
- Where
- 12 sites in Spain
- Volunteers
- 62 people
- Sponsor
- Spanish Oncology Genito-Urinary Group
Metastatic Breast Cancer, Advanced Breast Cancer
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
This is a study using sunitinib for patients ending treatment on a previous sunitinib malate protocol to continue to receive sunitinib.
- Conditions
- Metastatic Breast Cancer, Advanced Breast Cancer, Metastatic Castration Resistant Prostate Cancer, Metastatic Renal Cell Cancer
- Trial name
- NCT00428220
- Testing
- sunitinib
- Where
- 113 sites in United States, Argentina and 15 more
- Volunteers
- 223 people
- Sponsor
- Pfizer
Renal Cell Carcinoma
A Study of Atezolizumab (an Engineered Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) as Monotherapy or in Combination With Bevacizumab (Avastin®) Compared to Sunitinib (Sutent®) in Participants With Untreated Advanced Renal Cell Carcinoma
This multicenter, randomized, open-label study will evaluate the efficacy, safety and tolerability of atezolizumab as monotherapy or in combination with bevacizumab versus sunitinib in participants with histologically confirmed…
- Trial name
- IMmotion150 (NCT01984242)
- Testing
- Atezolizumab (MPDL3280A), an Engineered Anti-PD-L1 Antibody, Bevacizumab, Sunitinib
- Where
- 45 sites in United States, Czechia and 7 more
- Volunteers
- 305 people
- Sponsor
- Hoffmann-La Roche
Metastatic Renal Cell Carcinoma
RAD001 Plus Best Supportive Care (BSC) Versus BSC Plus Placebo in Patients With Metastatic Carcinoma of the Kidney Which Has Progressed After Treatment With Sorafenib and/or Sunitinib
To assess whether daily treatment with RAD001 could slow the growth and spread of metastatic carcinoma of the kidney. The safety of RAD001 was also to be studied in this trial.
- Trial name
- RECORD-1 (NCT00410124)
- Testing
- RAD001
- Where
- 93 sites in United States, Australia and 8 more
- Volunteers
- 416 people
- Sponsor
- Novartis Pharmaceuticals
Metastatic Renal Cell Carcinoma (mRCC)
Safety and Efficacy of Everolimus in Metastatic Renal Cell Carcinoma After Failure of First Line Therapy With Sunitinib or Pazopanib
Patients with metastatic renal cell carcinoma (mRCC) who failed first-line therapy with sunitinib or pazopanib was treated with everolimus. Efficacy and safety of everolimus was evaluated in these patients.
- Trial name
- NCT01514448
- Testing
- Everolimus (RAD001)
- Where
- 13 sites in Germany
- Volunteers
- 29 people
- Sponsor
- Novartis Pharmaceuticals
Renal Cell Carcinoma
A Study of Nivolumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma
The purpose of this study is to determine whether Nivolumab Combined with Cabozantinib is safe and effective compared to Sunitinib in previously untreated advanced or metastatic renal cell carcinoma
- Trial name
- CheckMate 9ER (NCT03141177)
- Testing
- Nivolumab, Cabozantinib, Sunitinib
- Where
- 135 sites in United States, Argentina and 16 more
- Volunteers
- 701 people
- Sponsor
- Bristol-Myers Squibb